N/A N=162 Tumor: Breast Ratio Study
Breast Cancer · LCIS · DCIS
Primary: Quality of Life as Measured by the Breast Q — 61.9; 57.6; 74.2; 64.2 score on a scale
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=257 Preoperative Treatment of Breast Cancer With Two Different Sequential Treatment Regimens
Breast Cancer
Primary: Number of Participants With a Pathological Complete Response — 21; 24; 99; 89 participants
Phase 2 N=37 Neoadjuvant Endocrine Therapy in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Node-Negative Breast Cancer
Breast Cancer · Invasive Breast Cancer
Primary: Change in Baseline of Cancer Cell Protein Levels of Human Epidermal Growth Factor Receptor (HER) Family Members (HER1-4) Following Neoadjuvant Endocrine Therapy. — 1…
N/A N=20 Tactile Breast Imaging Sensor for Tumor Malignancy Characterization
Breast Cancer
Primary: Size Error in Millimeters — 0 milimeters
Phase 2 N=43 Neoadjuvant Treatment of Breast Cancer
Breast Cancer
Primary: Overall Clinical Response to the Dose Dense Regimen — 43 Participants
Phase 1 N=82 Effect of Denosumab on Cellular Biomarkers in the Human Breast
Healthy Volunteer, Female, Breast
Primary: Log Ratio of Post-baseline to Baseline Ki-67 Index in Mammary Epithelial Cells — 0.084; -0.100; -0.081 log ratio — p=0.2966
Phase 3 N=163 Breast and Melanoma Trial With Lymphoseek to Identify Lymph Nodes
Breast Cancer · Melanoma
Primary: Concordance of Blue Dye and Lymphoseek — 1.0000 Proportion of Lymph Nodes
Phase 2 N=189 Selective Neoadjuvant Treatment According to Immunohistochemical Subtype for HER2 Negative Breast Cancer Patients
Breast Cancer
Primary: Pathological Response for Basal Group 2 — 16; 14; 5; 11 Participants
N/A N=36,444 Surveillance Imaging Modalities for Breast Cancer Assessment
Breast Cancer
Primary: Number of Breast Cancers Detected — 279; 27 cancers detected
N/A N=8 Assessing Response to Neoadjuvant Chemotherapy With HD PET/CT, Serum Glycomic Markers and Tissue Muc-1 Isoforms
Breast Cancer
Primary: Assess the Ability of the HD PET/CT to Predict Final Histopathologic NAC Response.
Phase 2 N=60 Feasibility Study of Intraoperative Imaging in Breast Cancer
Breast Cancer
Primary: (Phase A Only) Selection of Dose of LUM015 to be Used in Future Breast Trials — 2.1; 4.7; 4.2 Ratio
N/A N=45 ARFI, VisR and DDAI Ultrasound for Improving Discrimination of Malignant and Unresponsive Breast Cancer
Breast Cancer
Primary: Correlation of Peak Displacement (PD) for Detecting Malignancy — 4.5803; 8.628 microns — p=0.2988
Phase 2 N=30 Denosumab and MRI Breast Imaging
Breast Cancer
Primary: Relative Change of ≥ 5% in Breast Density at 6 Months — 13; 8; 4 Participants — p=0.026
Phase 2 N=12 Hybrid Molecular Imaging of ER in Breast Cancer Patients With DCIS
Breast Cancer · Ductal Carcinoma in Situ - Category
Primary: 18F-FES Uptake in DCIS — 1.43 SUV
Phase 2 N=23 A Study of Neoadjuvant Nivolumab + Palbociclib + Anastrozole in Post-Menopausal Women and Men With Primary Breast Cancer
Breast Cancer · Cancer
Primary: The Number of Participants With Dose Limiting Toxicities (DLT) in the Safety Run-in Phase — 0; 2; 0 Participants
Phase 2 N=234 Intraoperative Detection of Residual Cancer in Breast Cancer
Breast Cancer
Primary: Collect Data to Refine and Verify the Tumor Detection Algorithm. — 11.3 Percentage
N/A N=20 Phase IV Trial to Evaluate Breast Brachytherapy Using the Mammosite-Ml®
Breast Cancer · Ductal Carcinoma in Situ
Primary: Ipsilateral Recurrence Rate — 0 participants
N/A N=1,704 Radiologic Evaluation and Breast Density (READ)
Breast Cancer
Primary: Mammogram Recall for Additional Imaging — 11.3; 12.3; 9.8 percentage of women recalled
Phase 2 N=83 Neoadjuvant Treatment With Nab-paclitaxel for Patients With Stage II and III Luminal Breast Cancer
Breast Cancer
Primary: The Residual Cancer Burden Grade III (RCB-III). — 23; 37; 14; 6 Participants
Phase 3 N=521 Study of Nivolumab Versus Placebo in Combination With Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy in Participants With High-risk, Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor 2-Negative (HER2-) Primary Breast Cancer
Breast Cancer
Primary: Pathological Complete Response (pCR) Rate — 24.5; 13.8 Percentage of participants — p=0.0021
Phase 2 N=42 Chemoprevention Trial - Anastrozole in Ductal Carcinoma In Situ (DCIS) in Postmenopausal Women
DCIS
Primary: Number of Participants With a Change in Ki-67 Level — 15; 5; 3 Participants — p=0.004
Phase 2 N=49 Neoadjuvant GW572016 to Treat Breast Cancer
Breast Cancer
Primary: Clinical Response — 3; 30; 11; 3 participants
Phase 2 N=69 Study of Concurrent Paclitaxel and Radiation: Correlation of Tumor Profiles With Pathologic Response
Breast Cancer
Primary: Test the Clinical Effectiveness of Concurrent Paclitaxel and Radiation in a Multiethnic Cohort
N/A N=57 Supine MRI in Breast Cancer Patients Undergoing Upfront Surgery or Receiving Neoadjuvant Therapy
Breast Cancer
Primary: Correlation Between Prone Breast MRI for Estimation of Tumor Size and Final Pathology Tumor Size — 0.635 correlation coefficient
N/A N=89 Contrast-Enhanced Mammography for Breast Cancer Staging in Patients Referred for a Second Opinion
Breast Carcinoma · Invasive Breast Carcinoma
Primary: Accuracy of CEM for Incremental Cancer Detection in the Ipsilateral and Contralateral Breasts. — 41.4 % of malignancy in new CEM lesions
Phase 4 N=256 Effects of Tamoxifen in Premenopausal Women With Benign Breast Disease Not at High-Risk of Developing Breast Cancer
Benign Breast Disease · Fibrocystic Disease of Breast · Fibroadenoma
Primary: Number of Participants Analysed for Reduction in Lump Size ( 60% Reduction in Lump Size Considered to be a Satisfactory Response) — 63; 61; 54; 14 participants
Phase 2 N=124 Palbociclib in Molecularly Characterized ER-positive/HER2-negative Metastatic Breast Cancer
Metastatic Breast Cancer
Primary: Number of Participants With and Without Progression Free Survival (PFS) Events — 92; 30 Participants
Phase 2 N=72 Phase II Trial for Large ER-Negative Breast Cancers
Malignant Neoplasm of Female Breast
Primary: Overall Response Rate — 25; 21 Participants
Phase 4 N=60 PEMF and PEC Blocks in Mastectomy Reconstruction Patients
Breast Cancer Female
Primary: Score on Visual Analog Scale (VAS) - 1 Hour Post-intervention — 6.64; 6.67; 4.62; 6.93 score on a scale
Phase 2 N=35 Neoadjuvant Tamoxifen in Locally Advanced Breast Cancer in a Low/Middle Income Country
Breast Cancer · Breast Neoplasms
Primary: Number of Participants Who Were Successfully Accrued in the Study, as a Measure of Feasibility — 35 participants